Practitioner Education
Understanding the Endocannabinoid System
A professional primer on the body's native cannabinoid signaling network: its receptors, its endocannabinoids, its enzymes, and the history of its discovery.
ECS Receptor Overview
The Fundamentals
What Is the Endocannabinoid System?
The endocannabinoid system (ECS) is a biological signaling network found in all vertebrates. It regulates a broad range of physiological processes, including sleep, mood, appetite, and immune function, through a system of receptors, endogenous ligands, and metabolic enzymes.
Receptors
CB1 and CB2 are the primary ECS receptors. CB1 is concentrated in the CNS; CB2 is expressed throughout peripheral tissue, immune cells, and skin.
Endocannabinoids
Anandamide (AEA) and 2-AG are the body's own cannabinoid-like molecules. They are produced on demand in response to physiological need and bind to ECS receptors to modulate signaling.
Metabolic Enzymes
FAAH (fatty acid amide hydrolase) and MAGL (monoacylglycerol lipase) break down endocannabinoids after use. FAAH breaks down anandamide, and MAGL breaks down 2-AG.
Discovery & History
First Identified in 1988, Mapped Through the 1990s
The ECS was first identified by Dr. Allyn Howlett and William Devane in 1988 when they discovered the CB1 receptor. The endogenous ligand anandamide was identified in 1992 by Dr. Raphael Mechoulam — the same researcher who first isolated THC in 1964. Despite three decades of research, the ECS remains largely absent from standard medical and allied health curricula, leaving most practitioners without a foundational understanding of a system that influences nearly every major physiological process.
Clients ask about CBD. Knowing the history and the vocabulary of the ECS helps you answer those questions accurately and keep the conversation factual.
| Year | Discovery | Researcher |
|---|---|---|
| 1964 | THC isolated from cannabis | Raphael Mechoulam |
| 1988 | CB1 receptor identified in rat brain | Howlett & Devane |
| 1992 | Anandamide (AEA) isolated | Mechoulam et al. |
| 1993 | CB2 receptor cloned | Munro et al. |
| 1995 | 2-AG identified as second endocannabinoid | Mechoulam et al. |
| 2003 | ECS named; homeostatic role established | Di Marzo et al. |
Physiological Scope
A Regulatory System That Touches Nearly Every Organ System
The ECS is not a niche system. ECS receptors are expressed in the brain, spinal cord, peripheral nervous system, immune system, skin, gut, liver, cardiovascular system, reproductive system, and musculoskeletal tissue. This broad expression is why the system appears in so many areas of physiology research.
This table shows where the two receptor types are found in the body. It is an anatomy reference only and makes no statement about any ingredient or product.
| System | CB1 | CB2 |
|---|---|---|
| Central Nervous System | High | Low |
| Peripheral Nervous System | Moderate | High |
| Skin & Dermis | Low | High |
| Immune Cells | Low | High |
| Musculoskeletal Tissue | Low | High |
| Gut / GI Tract | High | Moderate |
Receptor Science
The Receptors and Enzymes of the ECS
The ECS has two primary receptors, CB1 and CB2, and two primary metabolic enzymes, FAAH and MAGL. The cards below summarize where each one is found and what it does within the body’s own signaling system.
CB1
Cannabinoid Receptor Type 1
Primarily expressed in the central nervous system: brain, spinal cord, and peripheral sensory neurons. Low expression in skin. CB1 was the first cannabinoid receptor identified, by Howlett and Devane in 1988.
CB2
Cannabinoid Receptor Type 2
Predominantly expressed in peripheral tissue: skin keratinocytes, mast cells, sebocytes, and peripheral immune cells. Low expression in the central nervous system. CB2 was cloned in 1993 by Munro and colleagues.
MAGL
Monoacylglycerol Lipase
MAGL is the enzyme that breaks down 2-AG after it has acted on ECS receptors. Together with FAAH, it keeps endocannabinoid signaling brief: endocannabinoids are produced on demand and rapidly degraded after use.
FAAH
Fatty Acid Amide Hydrolase
FAAH is the primary enzyme responsible for breaking down anandamide (AEA) after it has activated ECS receptors. It is an intracellular enzyme found in skin, brain, and liver.
| Component | Type | Endocannabinoid | Role | Key Function |
|---|---|---|---|---|
| CB1 | Receptor | Anandamide, 2-AG | Binding site | CNS signaling, appetite, mood |
| CB2 | Receptor | Anandamide, 2-AG | Binding site | Peripheral and immune signaling |
| MAGL | Enzyme | 2-AG | Breakdown | 2-AG degradation |
| FAAH | Enzyme | Anandamide | Breakdown | Anandamide degradation |
The two receptors and two enzymes above are textbook parts of human physiology. Nothing in this section describes what an ingredient or a product does.
The Body's Own Cannabinoids
Endocannabinoids: What the Body Produces Naturally
Endocannabinoids are lipid-based neurotransmitters produced on demand by the body in response to physiological need. Unlike classical neurotransmitters, they travel retrograde — from post-synaptic to pre-synaptic neurons — and are rapidly degraded after use.
Anandamide
AEA — "The Bliss Molecule"
Named from the Sanskrit word "ananda" (bliss), anandamide was the first endocannabinoid identified (1992). It is a partial agonist at CB1 and CB2 receptors. AEA is rapidly broken down by FAAH (fatty acid amide hydrolase).
2-Arachidonoylglycerol
2-AG — Full Agonist at CB1 & CB2
2-AG is present in the body at concentrations 170× higher than anandamide and acts as a full agonist at both CB1 and CB2 receptors. It plays a primary role in retrograde synaptic signaling and is the dominant endocannabinoid in immune modulation. 2-AG is degraded by MAGL (monoacylglycerol lipase).
Both endocannabinoids are made on demand and broken down quickly: anandamide by FAAH, and 2-AG by MAGL. The plant-derived cannabinoids defined in the next section are a separate subject.
Phytocannabinoid Terms
CBD & CBG: Phytocannabinoids Defined
Phytocannabinoids are cannabinoids made by plants, as distinct from the endocannabinoids the body makes for itself. CBD and CBG are two of the phytocannabinoids found in hemp. The notes below define the terms and nothing more.
CBD
Cannabidiol
CBD is one of the phytocannabinoids found in hemp. It is made by the plant, not by the body, so it is not part of the endocannabinoid system itself.
Full name: Cannabidiol.
Class: Phytocannabinoid, a plant-derived compound.
Source: The hemp plant, alongside CBG, THC, and CBC.
Not an endocannabinoid: The body does not make CBD. The body's own cannabinoid-like molecules are anandamide and 2-AG.
CBG
Cannabigerol
CBG is another phytocannabinoid found in hemp. Like CBD, it is made by the plant, not by the body.
Full name: Cannabigerol.
Class: Phytocannabinoid, a plant-derived compound.
Plant chemistry: The biosynthetic precursor to CBD, THC, and CBC.
Nickname: Called "the mother cannabinoid" because of that precursor role.
Endocannabinoids, such as anandamide and 2-AG, are made by the body. Phytocannabinoids, such as CBD and CBG, are made by plants. This page describes the body’s own system. It does not describe what any plant compound or product does.
For Your Practice
Why the ECS Matters for Your Practice
Clients ask about CBD. A working knowledge of the endocannabinoid system and its vocabulary helps practitioners read labels and lab reports and keep those conversations factual.
Shared Vocabulary
Receptors, endocannabinoids, and metabolic enzymes are the three parts of the ECS. Knowing the terms lets you follow the research literature and answer questions in plain language.
Two Kinds of Cannabinoid
Anandamide and 2-AG are endocannabinoids, made by the body. CBD and CBG are phytocannabinoids, made by the hemp plant. Keeping the two groups separate keeps client conversations accurate.
Lab Reports
Kannaco topicals are third-party lab tested, and each batch has its own Certificate of Analysis (COA). The COA is the document to reference when a client asks what is in a product.
A Recent Field
The CB1 receptor was identified in 1988, anandamide in 1992, CB2 in 1993, and 2-AG in 1995. The field is recent, which is why it is largely absent from standard curricula.
How We Describe Our Topicals
Kannaco topicals are applied to the skin, and we do not claim that they treat, cure or prevent any condition. Describe them by feel, ingredients, and lab testing.
Client Conversations
Start with physiology, not the product. Explain that the body makes its own cannabinoid-like molecules, then describe the product for what it is: a cream, oil or roll-on applied to the skin.
Practitioner FAQ
Frequently Asked Questions
Common questions about the endocannabinoid system and its terminology, answered for practitioners.
What is the endocannabinoid system and when was it discovered?
The endocannabinoid system (ECS) was formally identified in the early 1990s by Dr. Raphael Mechoulam and colleagues at Hebrew University, following the isolation of THC in 1964. The CB1 receptor was cloned in 1990, CB2 in 1993, and the first endocannabinoid — anandamide — was characterized in 1992. The ECS is a retrograde neuromodulatory system present in virtually all vertebrates, regulating homeostasis across the nervous, immune, and endocrine systems. Its late discovery (relative to other receptor systems) explains why it is not covered in most medical and allied health curricula — a gap that practitioners are increasingly working to address.
Does the ECS depend on plant-derived compounds?
No. The ECS runs on endocannabinoids, lipid-based neurotransmitters produced by the body itself. The two primary endocannabinoids are anandamide (AEA) and 2-arachidonoylglycerol (2-AG). The ECS functions continuously in the absence of any plant-derived compounds.
What is the difference between CB1 and CB2 receptors?
CB1 receptors are primarily expressed in the central nervous system: brain, spinal cord, and peripheral sensory neurons. CB2 receptors are predominantly expressed in peripheral tissue: skin keratinocytes, mast cells, immune cells, bone, and synovial tissue. Both respond to the endocannabinoids the body makes for itself, anandamide and 2-AG.
What is the difference between an endocannabinoid and a phytocannabinoid?
An endocannabinoid is a cannabinoid-like molecule that the body produces for itself, such as anandamide or 2-AG. A phytocannabinoid is a cannabinoid produced by a plant, such as CBD, CBG, or THC. This page describes the body’s own system. It does not describe what any plant compound or product does.
How are endocannabinoids broken down?
By metabolic enzymes. FAAH (fatty acid amide hydrolase) is the primary enzyme that breaks down anandamide, and MAGL (monoacylglycerol lipase) breaks down 2-AG. Endocannabinoids are produced on demand and are rapidly degraded after use.
How do CBD and CBG relate to each other?
Both are phytocannabinoids, made by the plant and not by the body. CBG is the biosynthetic precursor to CBD, THC, and CBC, which has earned it the designation "the mother cannabinoid." That is plant chemistry, and it is a separate subject from the body’s own endocannabinoid system.
What do Kannaco lab reports show for THC?
Kannaco topicals are third-party lab tested, with a batch-specific Certificate of Analysis (COA). All three formulas, Pro Cream, Pro Roll-On and Cooling Cream: 0.0% THC. For any product, refer to the COA for that batch.
Is this page medical advice?
No. It is general background on human physiology, written for licensed practitioners. Kannaco topicals are applied to the skin, and we do not claim that they treat, cure or prevent any condition.
How should I explain the ECS to a client?
Start with physiology, not the product. Explain that the body produces its own cannabinoid-like molecules (anandamide and 2-AG), that they act on receptors called CB1 and CB2, and that enzymes break them down after use. When the conversation turns to a product, describe it for what it is: a cream, oil or roll-on for the skin, with a published ingredient list and a batch-specific lab report.
Where can I find peer-reviewed research on the ECS?
PubMed (pubmed.ncbi.nlm.nih.gov) is the primary database for peer-reviewed ECS research. A useful search term is "endocannabinoid system." Reference papers include Tóth et al. (2019) on the cutaneous ECS. The International Cannabinoid Research Society (ICRS) also publishes practitioner-oriented resources. Kannaco’s Practitioner Downloads page provides curated reference documents and client education materials for your practice.